MyoKardia, Inc. (NASDAQ:MYOK) is scheduled to be announcing its earnings results on Monday, November 6th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter.

MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.04). MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The business had revenue of $5.60 million during the quarter, compared to analyst estimates of $6.73 million. During the same period last year, the company earned ($0.37) EPS. The business’s revenue for the quarter was up 60.0% on a year-over-year basis. On average, analysts expect MyoKardia to post $-1.6 EPS for the current fiscal year and $-1.44 EPS for the next fiscal year.

Shares of MyoKardia, Inc. (MYOK) traded up 0.066% during trading on Monday, hitting $37.825. The stock had a trading volume of 13,127 shares. The stock’s 50 day moving average is $41.45 and its 200-day moving average is $41.45. MyoKardia, Inc. has a 12-month low of $10.55 and a 12-month high of $49.55. The company’s market cap is $1.19 billion.

Several equities research analysts have recently issued reports on MYOK shares. Zacks Investment Research cut MyoKardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Credit Suisse Group restated an “outperform” rating and set a $55.00 price objective (up previously from $45.00) on shares of MyoKardia in a report on Tuesday, September 19th. TheStreet upgraded MyoKardia from a “d+” rating to a “c” rating in a report on Thursday, July 6th. BidaskClub upgraded MyoKardia from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Cowen and Company raised their price objective on MyoKardia from $28.00 to $56.00 and gave the stock an “outperform” rating in a report on Monday, August 7th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. MyoKardia presently has an average rating of “Buy” and a consensus price target of $55.00.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at

In related news, CEO Anastasios Gianakakos sold 4,300 shares of MyoKardia stock in a transaction on Friday, August 4th. The stock was sold at an average price of $16.62, for a total value of $71,466.00. Following the transaction, the chief executive officer now owns 512,463 shares in the company, valued at $8,517,135.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Sanofi bought 350,000 shares of MyoKardia stock in a transaction that occurred on Monday, August 14th. The stock was purchased at an average price of $35.50 per share, for a total transaction of $12,425,000.00. The disclosure for this purchase can be found here. Insiders sold 1,753,513 shares of company stock worth $73,876,995 in the last quarter. 33.40% of the stock is owned by insiders.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Earnings History for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with's FREE daily email newsletter.